Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reflects a company in transition, with positive developments in cost reduction, strategic partnerships, and business model shift. However, the absence of immediate revenue generation, potential risks in market acceptance, and lack of shareholder return plans balance the positives. The lack of questions during the Q&A session suggests a neutral analyst sentiment. Given these factors, the stock price is likely to remain stable in the short term.
R&D Costs $1.6 million (54% decrease from $3.6 million in the same period last year) due to the transition from R&D to commercialization.
Marketing Expenses $700,000 (56% decrease from $1.6 million in the prior year period) primarily due to lower public relations and manpower costs.
General and Administrative Expenses $2 million (9% decrease from $2.2 million in the prior year period) reflecting cost management efforts.
Net Loss $4.4 million or $1.10 per ordinary share (54% decrease from $9.5 million or $5 per ordinary share in the first half of 2023) driven by reductions in R&D and marketing expenses.
Net Cash Used in Operating Activities $4.4 million (decrease from $7.5 million in the prior year period) indicating improved cash management.
Cash and Equivalents $5.4 million at the end of the first half of 2024 (increase from $4.2 million at the end of 2023) showing a stronger cash position.
New Product Launches: Launched a new line of vegan fish salads in partnership with Sherry Herring, utilizing SH-Fish premix blends. Developing a new plant-based white fish kebab line with Premazon, integrating SH-Fish premix blend.
Market Expansion: Secured a multimillion-dollar agreement with Wyler Farm for alternative protein production in Israel. Established a partnership with ITRI in Taiwan to develop food products tailored for Taiwanese cuisine.
Operational Efficiencies: Reduced operating expenses by over 50% due to completion of major R&D work. R&D costs decreased from $3.6 million to $1.6 million year-over-year, a 54% reduction. Marketing expenses reduced by 56% from $1.6 million to $700,000. General and administrative expenses decreased by 9% from $2.2 million to $2 million.
Strategic Shifts: Shifted focus to two key revenue streams: selling 3D printers and meat/fish premix blends. Transitioned from R&D to commercialization, securing four commercialization agreements.
Business Model Shift Risks: The transition from R&D to commercialization may face challenges in execution and market acceptance, particularly as the company shifts focus to B2B revenue streams.
Competitive Pressures: The company may encounter significant competition in the alternative protein market, which could impact its ability to secure additional partnerships and market share.
Regulatory Issues: As the company operates in the food industry, it may face regulatory hurdles that could delay product launches or increase compliance costs.
Supply Chain Challenges: The reliance on partners for production and distribution may expose the company to supply chain disruptions, affecting the timely rollout of products.
Economic Factors: Economic downturns or shifts in consumer preferences towards alternative proteins could impact sales and revenue projections.
Financial Stability: Despite reduced operating expenses, the company still reported a net loss of $4.4 million, indicating ongoing financial risks as it seeks to achieve profitability.
Key Revenue Streams: Focus on selling 3D printers and meat/fish premix blends to the foodservice industry.
Recurring Revenue Agreements: Secured first recurring revenue strategic agreement followed by three similar agreements.
Commercialization Agreements: Four significant commercialization agreements secured with Wyler Farm, ITRI, Sherry Herring, and Premazon.
Global Expansion Strategy: Partnership with ITRI to develop food products tailored for Taiwanese cuisine.
Product Rollout: Production of new plant-based products set to begin soon, with initial revenue expected by late 2024 or early 2025.
Revenue Expectations: Anticipate modest revenue generation to commence in late 2024 or early 2025, with accelerated growth projected for 2025.
R&D Expenses: R&D costs reduced to $1.6 million in H1 2024 from $3.6 million in H1 2023, a 54% reduction.
Net Loss: Net loss decreased by 54% to $4.4 million in H1 2024 compared to $9.5 million in H1 2023.
Cash Position: Entered H1 2024 with $5.4 million in cash and equivalents, up from $4.2 million at the end of 2023.
Future Agreements: Progress towards finalizing a global commercial agreement expected to be announced by early 2025.
Shareholder Return Plan: None
The earnings call summary reflects a company in transition, with positive developments in cost reduction, strategic partnerships, and business model shift. However, the absence of immediate revenue generation, potential risks in market acceptance, and lack of shareholder return plans balance the positives. The lack of questions during the Q&A session suggests a neutral analyst sentiment. Given these factors, the stock price is likely to remain stable in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
